Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline Gilead Sciences, Inc. and Lakefront Biotherapeutics NV announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases.…
GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations As theranostics adoption acceleratesi and radiopharmaceutical demand grows,ii healthcare systems are under increasing pressure to scale nuclear medicine operations while improving diagnostic confidence and workflow efficiency. At…
Foundation Medicine Showcases Innovation at 2026 ASCO® Annual Meeting Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced it will showcase data across its portfolio of high-quality comprehensive genomic profiling tests at the 2026 American Society of Clinical Oncology (ASCO)…
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform Foundation Medicine, Inc., a global, patient-focused precision medicine company and an independent affiliate of Roche, announced it is set to expand its monitoring portfolio with…
Alchemedicine and Asahi Kasei Pharma Forge Exclusive Global License for HiSAP Lead Compounds Alchemedicine Inc. (Head Office: Tsukuba, Ibaraki; President: Keigo Tanaka; hereafter “Alchemedicine”) and Asahi Kasei Pharma Corporation (Head Office: Chiyoda-ku, Tokyo; President: Yoshikazu Aoki; hereafter “Asahi Kasei Pharma”)…
Long-Term Data Demonstrate Safety and Preliminary Efficacy of Investigational One-Time Gene Therapy in Patients with Non-Ischemic Heart Failure AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced the publication…
ReCode Therapeutics, a clinical-stage genetic medicines company pioneering tissue-specific delivery technologies to advance the next generation of mRNA and gene correction therapeutics, announced today that it has secured more than $29 million in new financing. Alongside this financial update, the…
TandemAI and Perpetual Medicines Merge to Advance AI and Physics-Driven Drug Discovery Newly combined company will broaden capabilities in small molecule and peptide therapeutics with expanded leadership and integrated technology platforms In a strategic move that strengthens innovation at the…
California University of Science and Medicine Celebrates 2025 MD Match Day Achievements The California University of Science and Medicine (CUSM) marked a significant milestone in the academic journey of its 2025 graduating class during the highly anticipated Match Day event.…
LG Chem has made a significant global impact by highlighting the successes of its infertility treatment brands. On August 8, the company announced the successful conclusion of the FAME (Fertility Advancement MEeting) Global symposium in Amsterdam, Netherlands. This event drew…
insitro Presents New Data Demonstrating Its AI-Discovered MASH Candidate Shows Anti-Fibrotic Signal Beyond Liver-Fat Reduction at the American Diabetes Association 86th Scientific Sessions insitro, the physical AI company unlocking causal human biology, presented new preclinical data from its metabolic dysfunction-associated…
OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions OrsoBio, Inc. a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, announced new clinical and preclinical data…